Completed PHASE3 INTERVENTIONAL 2-arm NCT00426777

Efficacy Study of Risedronate to Prevent Cancer Treatment-Induced Bone Loss in Prostate Cancer

A Randomized, Single-blind, Placebo-controlled, Multicentre Study to Evaluate the Effect of Risedronate and Placebo on Bone Mineral Density in Men Undergoing Androgen Deprivation Therapy With Leuprolide Acetate

Sponsor: CMX Research

Conditions Prostate Cancer

Interventions Control risedronate

Updated 6 times since 2017 Last updated: Feb 2, 2012 Started: Jan 31, 2007 Primary completion: Jan 31, 2009 Completion: Feb 28, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Prostate Cancer and is currently completed. CMX Research leads this study, which shows 6 recorded versions since 2007 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jan 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CMX Research
Sanofi

Data source: CMX Research

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Barrie, Canada , Brampton, Canada , Brantford, Canada , Burlington, Canada , Fredericton, Canada , Greater Sudbury, Canada , Greenfield Park, Canada , Guelph, Canada , Kelowna, Canada , Mississauga, Canada and 10 more locations